<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin Ò Outcomes Registry and Experience (EU-CORE)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-07-14">July 14, 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Achyut</forename><forename type="middle">Guleri</forename><surname>Riccardo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Utili</forename><surname>Pascal</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dohmen</forename><surname>Nicola</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Petrosillo</forename><surname>Cornelia</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Piper</forename><surname>Rashidkhan</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Pathan</forename><surname>Kamal Hamed</surname></persName>
							<email>kamal.hamed@novartis.com</email>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Guleri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Utili</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">O R N O C</forename><surname>Monaldi-U</surname></persName>
						</author>
						<author>
							<persName><surname>Medicina Infettivologica</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Dohmen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">N</forename><surname>Petrosillo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">I</forename><forename type="middle">N M I</forename><surname>''</surname></persName>
						</author>
						<author>
							<persName><forename type="first">L</forename><forename type="middle">O C</forename><surname>Spallanzani''-U</surname></persName>
						</author>
						<author>
							<persName><surname>Infezioni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Pathan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Hamed</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Lancashire Cardiac Centre</orgName>
								<orgName type="institution" key="instit2">Blackpool Teaching Hospitals NHS Foundation Trust</orgName>
								<address>
									<settlement>Blackpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">dei Trapianti</orgName>
								<address>
									<addrLine>Via L. Bianchi</addrLine>
									<settlement>Naples</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Charite ´-Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Sistemiche e dell&apos;Immunodepresso (II Divisione)</orgName>
								<orgName type="institution">C. Piper Herz-und Diabeteszentrum NRW</orgName>
								<address>
									<settlement>Rome, Bad Oeynhausen</settlement>
									<country>Italy, Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">Novartis Healthcare Pvt. Ltd</orgName>
								<address>
									<settlement>Hyderabad</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<settlement>East Hanover</settlement>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin Ò Outcomes Registry and Experience (EU-CORE)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-07-14">July 14, 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">E6CB9CACFCA16E6A38B533B0703520F3</idno>
					<idno type="DOI">10.1007/s40121-015-0075-9</idno>
					<note type="submission">Received: June 1, 2015 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Daptomycin</term>
					<term>Endocarditis</term>
					<term>EU-CORE</term>
					<term>Left-sided endocarditis</term>
					<term>Right-sided endocarditis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Introduction: The European Cubicin Ò Outcomes Registry and Experience (EU-CORE SM ) was a retrospective, non-interventional, multicenter study which evaluated the safety and effectiveness of daptomycin therapy in patients with Gram-positive infections including infective endocarditis (IE).</s><s>Methods: Data from the EU-CORE registry were collected for patients with IE who had received at least one dose of daptomycin between January 2006 and April 2012, across 18 countries in Europe (12), Latin America (5) and Asia (1).</s><s>Clinical outcomes were assessed as success (cured or improved), failure or nonevaluable.</s><s>Adverse events (AEs) were recorded during treatment and for up to 30 days posttreatment; follow-up data were collected for 2 years.</s><s>Results: Of 6075 patients included in the EU-CORE registry, 610 were diagnosed with IE as primary infection; 149 (24.4%) right-sided IE (RIE), 414 (67.9%) left-sided IE (LIE), and 47 (7.7%) with both right-and left-sided IE (BRLIE).</s><s>Overall clinical success was achieved in 80.0% of patients (RIE 88.6%, LIE 76.6% and BRLIE 82.9%).</s><s>Success rates for methicillinresistant Staphylococcus aureus (MRSA) infections were 90.9%, 71.7% and 66.6% in patients with RIE, LIE and BRLIE, respectively.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>patients followed for up to 2 years was 86.7% (RIE 93.5%, LIE 88.3% and BRLIE 77.8%).</s><s>AEs deemed possibly related to daptomycin in the investigator's opinion were reported in 2 (1.3%) RIE, 18 (4.3%)</s><s>LIE and 1 (2.1%)</s><s>BRLIE patients.</s><s>There were 11 (1.8%) patients (2 with RIE, 8 with LIE and 1 with BRLIE) with AEs of creatine phosphokinase elevation reported as possibly</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Infective endocarditis (IE), primarily caused by Gram-positive bacteria, is associated with a high rate of morbidity and mortality, which represents a large burden to the healthcare system <ref type="bibr" target="#b0">[1]</ref>.</s><s>Hospitalizations due to IE rose from <ref type="bibr">25,511 to 38,976 between 1998 and 2009</ref> in the United States, with increase in serious neurologic and cardiac complications <ref type="bibr" target="#b1">[2]</ref>.</s><s>Mortality associated with IE ranges between 15% and 20% <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>.</s></p><p><s>Although IE is associated with a variety of microorganisms, staphylococci, streptococci and enterococci account for the majority of cases <ref type="bibr" target="#b5">[6]</ref>.</s><s>Staphylococcus aureus is the most commonly detected causative agent <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>A cohort study showed that among 2781 patients with IE, the most common pathogens were S. aureus (31%), viridans group streptococci (17%), enterococci (10%), coagulase-negative staphylococci (11%), Streptococcus bovis (6%), and other streptococci (6%) <ref type="bibr" target="#b4">[5]</ref>.</s></p><p><s>Methicillin-resistant S. aureus (MRSA) has emerged as a common pathogen in both healthcare and community-acquired infections <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>Community-acquired MRSA has been found to be particularly responsible for causing IE in patients with human immunodeficiency virus <ref type="bibr" target="#b8">[9]</ref>.</s><s>Another multinational study reported an increase in the relative proportion of both hospital-and community-onset of MRSA bloodstream infections <ref type="bibr" target="#b9">[10]</ref>.</s><s>MRSA infections, including IE, are associated with higher levels of mortality compared to methicillin-susceptible S. aureus (MSSA) <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>The resistance of pathogens to commonly used antibiotics is one of the major public health problems, and the successful treatment of IE remains challenging.</s><s>Patients with IE require an aggressive treatment approach with effective antibiotics or a combination of effective antibiotics and surgery <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref>.</s></p><p><s>Daptomycin is a bactericidal, cyclic lipopeptide that is active against Grampositive bacteria.</s><s>The mechanism of action involves binding (in the presence of calcium ions) to bacterial membranes of both growing and stationary phase cells causing depolarization and leading to a rapid inhibition of protein, deoxyribonucleic acid and ribonucleic acid synthesis.</s><s>This results in bacterial cell death with negligible cell lysis <ref type="bibr" target="#b15">[16]</ref>.</s></p><p><s>Daptomycin is associated with concentrationdependent activity, hence a high dose of daptomycin has the ability to penetrate bacterial biofilm and may help to prevent the emergence of bacterial resistance <ref type="bibr" target="#b0">[1]</ref>.</s></p><p><s>Daptomycin is approved for the treatment of complicated skin and skin-structure infections caused by Gram-positive pathogens, bacteremia and right-sided IE caused by S. aureus <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b17">18]</ref>.</s></p><p><s>Infective endocarditis can affect the right side (RIE), left side (LIE) or both sides (BRLIE) of the heart.</s><s>Reports from earlier studies suggest that daptomycin can be useful in the treatment of both LIE as well as RIE <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref>, although the drug is only indicated for use in patients with RIE.</s></p><p><s>The objective of this analysis from the</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and Data Collection</head><p><s>This analysis includes patients enrolled in EU-CORE, a non-interventional, multicenter, retrospective, patient registry designed to collect real-world outcome data on patients who had received at least one dose of daptomycin for the treatment of a serious Gram-positive bacterial infection.</s><s>The protocol was approved by the health authority and the Institutional Review Board (IRB) or Ethics Committee (EC) in each country and written informed consent was obtained according to the requirements of the IRB or EC and/or the local data privacy regulations.</s><s>Patients who might have received daptomycin as part of a controlled clinical trial were excluded from retrospective collection of data.</s><s>Details of the EU-CORE registry have been published previously <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref>.</s></p><p><s>The data from the registry were collected using standardized case report forms for patients with IE who had received at least one dose of daptomycin between January 2006 and April 2012.</s><s>Supplementary and 2-year follow-up (until 2014) data were collected for patients with IE.</s><s>Patients were included from sites across 18 countries: Argentina, Austria, Brazil, Bulgaria, Colombia, France, Germany, Greece, India, Italy, Mexico, Romania, Russia, Slovenia, Spain, Turkey, United Kingdom, and Venezuela.</s><s>Data were collected from the registry for those patients who received daptomycin treatment for IE as a primary infection and for whom this treatment was initiated and completed within the course of the registry reporting period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Outcomes and Safety</head><p><s>Clinical outcomes were assessed by investigators at the end of therapy as cured, improved, failed, or non-evaluable according to the following protocol-defined criteria: cured, clinical signs and symptoms resolved, no additional antibiotic therapy was necessary, or infection cleared with a negative culture reported; improved, partial resolution of clinical signs and symptoms and/or additional antibiotic therapy was warranted; failed, inadequate response to daptomycin therapy, worsening or new/recurrent signs and symptoms, need for a change in antibiotic therapy, or a positive culture reported at the end of therapy; and non-evaluable, unable to determine response due to insufficient information.</s><s>Clinical success was defined as outcomes cured or improved.</s><s>Time to improvement was also recorded.</s><s>The reasons for stopping daptomycin therapy and other antibiotics prescribed following daptomycin were also collected <ref type="bibr" target="#b10">[11]</ref>.</s><s>The diagnosis of IE was done according to modified Duke criteria <ref type="bibr" target="#b25">[25]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Outcomes</head><p><s>In this retrospective study, data from 610 patients with IE as well as 185 patients with  Clinical success rate was achieved in 132 (88.6%), 317 (76.6%) and 39 (83.0%) patients with RIE, LIE and BRLIE infections, respectively (Fig. <ref type="figure">1</ref>).</s><s>Treatment failure rates were low (4.3-8.7%)</s><s>across all types of IE.</s><s>Clinical success rate in 107 (92.2%) patients treated with daptomycin doses C8 mg/kg/day was higher compared with lower doses.</s><s>There was a trend towards higher rates of success as daptomycin doses increased (Table <ref type="table" target="#tab_5">4</ref> remained relapse free at the end of the 2-year follow-up period (Fig. <ref type="figure" target="#fig_0">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>An overview of AEs is presented in    Data from this analysis demonstrate that daptomycin was successful for the treatment of patients with IE caused by Gram-positive bacteria, including MRSA.</s><s>This finding is consistent with the earlier published reports <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b27">27]</ref>.</s><s>Overall, clinical success rates were high, demonstrating effective use of daptomycin to treat IE.</s><s>In this analysis, there was a trend towards higher success rate with higher daptomycin doses C8 mg/kg/day (maximum dose was 12 mg/kg/day) compared with lower doses.</s></p><formula xml:id="formula_0">Blood CPK increased 2 (1.3) 8 (1.9) 1 (2.1) Myalgia 1 (0.7) - - Agranulocytosis - 1 (0.2) - Eosinophilia - 1 (0.2) - Eye pain - 1 (0.2) - Mouth ulceration - 1 (0.2) - Cholestasis - 1 (0.2) - Pneumonia - 1<label>(0.2) - Rhabdomyolysis - 1 (0.2) - Eosinophilic pneumonia - 2 (0.5)</label></formula><p><s>This was consistent with a previous report <ref type="bibr" target="#b20">[21]</ref>.</s><s>Hence, the use of higher doses of daptomycin C8 mg/kg/day may result in better treatment outcome against IE.</s><s>This supports recommendations from international treatment guidelines for the use of higher doses of daptomycin in the treatment of patients with IE <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b28">28]</ref>.</s><s>Further exploratory analyses will be required to assess outcome by patients underlying disease status, and whether treatment was administered as first or second line.</s></p><p><s>Data from 414 patients with LIE were collected and analyzed in this analysis.</s><s>The results were similar to those of 149 patients with RIE and 47 patients with BRLIE.</s><s>In an observational cohort study, out of 178 patients with LIE, 29 received daptomycin and 149 received standard-of-care (SOC) therapy (e.g., penicillins, vancomycin, ampicillin, aminoglycosides).</s><s>There was a trend towards better outcome with higher doses of daptomycin compared to SOC therapy for patients with LIE <ref type="bibr" target="#b20">[21]</ref>, which is consistent with our findings.</s><s>Although daptomycin is not currently approved for the treatment of LIE, data from the present analysis have shown that daptomycin was used successfully for the treatment of LIE and BRLIE with a trend towards higher clinical success rates with higher daptomycin doses.</s><s>Therefore, data from this analysis suggest that daptomycin may be effective for the treatment of LIE and BRLIE.</s><s>The most commonly encountered causative agent was S. aureus, followed by S. epidermidis.</s></p><p><s>There was a higher proportion of enterococcal infection in patients with LIE than in RIE and BRLIE.</s><s>Also, there was a broader range of streptococcal infections in LIE than in RIE or BRLIE.</s><s>In this study, MSSA was more commonly isolated than MRSA from patients with IE.</s></p><p><s>Patients with IE who had complicated MSSA and MRSA infections and received daptomycin therapy had high success rates.</s><s>These results are consistent with the findings from an earlier in vitro study on IE model which showed that daptomycin had better bactericidal activity against the biofilm-forming MRSA compared with vancomycin <ref type="bibr" target="#b29">[29]</ref>.</s><s>Data from a prospective cohort study reported that the mortality of patients with IE infections caused by MRSA isolates was high with vancomycin minimum inhibitory concentration of 2 mg/L (determined by Etest) <ref type="bibr" target="#b30">[30]</ref>.</s><s>Daptomycin at higher doses may be considered as first-line therapy to manage both MSSA and MRSA infections in patients with IE, which was also mentioned in an earlier published report <ref type="bibr" target="#b31">[31]</ref>.</s><s>In an in vitro study, it was observed that daptomycin in combination with b-lactams enhanced efficacy of anti-MRSA therapeutic options against daptomycinresistant MRSA infections <ref type="bibr" target="#b32">[32]</ref>.</s><s>The results of another in vitro study showed that the combination of high doses of daptomycin with fosfomycin was effective in the treatment of left-sided endocarditis (both native and prosthetic valves) caused by MSSA or MRSA infections <ref type="bibr" target="#b33">[33]</ref>.</s><s>In the present study, the notable finding was that the clinical success rates remained high in patients with reported longterm follow-up results for up to 2 years.</s></p><p><s>This study has limitations due to its retrospective and non-comparative design.</s><s>It was not as strictly controlled as a randomized controlled trial.</s><s>Analysis was not conducted to provide statistical outcomes, although it is very difficult to conduct controlled trials in IE patients.</s><s>All patients with at least one dose of daptomycin were included, however, it should be noted that the correct course of treatment for daptomycin lasts between 4 and 6 weeks.</s><s>Some patients included in the registry might have received other antibiotics besides daptomycin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p><s>These results of real-world experience from the EU-CORE registry showed that patients with IE were treated successfully with daptomycin.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig. 2 Kaplan-Meier survival curve for patients with infective endocarditis and/or foreign body intracardiac/intravascular device infection with long-term follow-up</s></p></div></figDesc><graphic coords="9,91.88,77.53,397.44,254.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Daptomycin was well tolerated and effective for the treatment of LIE and BRLIE in addition to the approved indication of RIE, which provides evidence that daptomycin is a potential treatment option in the management of RIE, LIE and BRLIE.</s><s>Data showed that daptomycin is effective for treating Gram-positive infections, including MRSA infections.</s><s>The majority of patients with available long-term data remained relapse free during the 2-year follow-up period.</s><s>authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.</s><s>Medical writing support was provided by Novartis Global Medical and Clinical Services medical writers Rajeeb Ghosh and Farid Khalfi.</s><s>Funding for writing was provided by Novartis Pharm AG.</s><s>Conflict of interest.</s><s>Achyut Guleri received fees for advisory boards and speakers panels from Novartis, and consultancy fees from Astellas, AstraZeneca, MSD, and Schering-Plough.</s><s>He also received support to attend scientific conferences including accommodation and travel payments from BD, Carefusion UK, Janssen-Cilag, and MSD.</s><s>Riccardo Utili received from Novartis a research grant, fees for advisory boards and speakers panels, and support to attend meetings including accommodation and travel payments.</s><s>Pascal Dohmen received a research grant and fees for speakers panels from Novartis.</s><s>He also received grants from other companies.</s><s>Nicola Petrosillo received speakers fees from Cepheid and Astellas.</s><s>He is also a member of the board of Cilag and MSD.</s><s>Cornelia Piper has no conflicts of interest to declare.</s><s>Rashidkhan Pathan is an employee of Novartis Healthcare Pvt. Ltd.</s><s>Kamal Hamed is an employee of Novartis Pharmaceuticals Corporation.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1</head><label>1</label><figDesc><div><p><s>Patient disposition and analysis sets in the EU-CORE study (safety population) BRLIE both right-and left-sided infective endocarditis, EU-CORE European Cubicin Ò Outcomes Registry and Experience, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis</s></p></div></figDesc><table><row><cell>Patient disposition</cell><cell>RIE</cell><cell>LIE</cell><cell>BRLIE</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Infective endocarditis patients in EU-CORE</cell><cell>149 (100)</cell><cell>414 (100)</cell><cell>47 (100)</cell></row><row><cell>Completed daptomycin therapy</cell><cell>94 (63.1)</cell><cell>244 (58.9)</cell><cell>29 (61.7)</cell></row><row><cell>Primary reason for stopping daptomycin therapy</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Switched therapy</cell><cell>36 (24.2)</cell><cell>59 (14.3)</cell><cell>9 (19.1)</cell></row><row><cell>Adverse event</cell><cell>4 (2.7)</cell><cell>30 (7.2)</cell><cell>2 (4.3)</cell></row><row><cell>Failure</cell><cell>4 (2.7)</cell><cell>17 (4.1)</cell><cell>2 (4.3)</cell></row><row><cell>Unable to determine</cell><cell>1 (0.7)</cell><cell>17 (4.1)</cell><cell>2 (4.3)</cell></row><row><cell>Other</cell><cell>10 (6.7)</cell><cell>46 (11.1)</cell><cell>3 (6.4)</cell></row><row><cell>Unknown</cell><cell>-</cell><cell>1 (0.2)</cell><cell>-</cell></row><row><cell>Entered safety population</cell><cell>149 (100)</cell><cell>414 (100)</cell><cell>47 (100)</cell></row><row><cell>Entered efficacy population</cell><cell>149 (100)</cell><cell>414 (100)</cell><cell>47 (100)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2</head><label>2</label><figDesc><div><p><s>Demographic and clinical characteristics (safety population)</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell cols="2">Patients treated with daptomycin</cell><cell></cell></row><row><cell></cell><cell>RIE</cell><cell>LIE</cell><cell>BRLIE</cell></row><row><cell></cell><cell>N 5 149</cell><cell>N 5 414</cell><cell>N 5 47</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median (range)</cell><cell>58.0 (1-90)</cell><cell>62.0 (10-91)</cell><cell>63.0 (24-87)</cell></row><row><cell>\65, n (%)</cell><cell>93 (62.4)</cell><cell>227 (54.8)</cell><cell>(53.2)</cell></row><row><cell>C65, n (%)</cell><cell>56 (37.6)</cell><cell>187 (45.2)</cell><cell>(46.8)</cell></row><row><cell>C75, n (%)</cell><cell>28 (18.8)</cell><cell>82 (19.8)</cell><cell>(34.0)</cell></row><row><cell>Sex, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Female</cell><cell>45 (30.2)</cell><cell>154 (37.2)</cell><cell>(36.2)</cell></row><row><cell>Male</cell><cell>104 (69.8)</cell><cell>260 (62.8)</cell><cell>(63.8)</cell></row><row><cell>Race, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Caucasian</cell><cell>124 (83.2)</cell><cell>355 (85.7)</cell><cell>(85.1)</cell></row><row><cell>Other a</cell><cell>14 (9.4)</cell><cell>28 (6.8)</cell><cell>(4.3)</cell></row><row><cell>Unknown</cell><cell>11 (7.4)</cell><cell>31 (7.5)</cell><cell>(10.6)</cell></row><row><cell>Body weight (kg)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median (range)</cell><cell>68.0 (6-98)</cell><cell>73.0 (25-120)</cell><cell>70.0 (43-93)</cell></row><row><cell>Setting prior to daptomycin therapy, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hospital</cell><cell>133 (89.3)</cell><cell>389 (94.0)</cell><cell>(91.5)</cell></row><row><cell>Nursing home/extended care</cell><cell>-</cell><cell>-</cell><cell>(2.1)</cell></row><row><cell>Community</cell><cell>14 (9.4)</cell><cell>24 (5.8)</cell><cell>(4.3)</cell></row><row><cell>Unknown</cell><cell>-</cell><cell>-</cell><cell>(2.1)</cell></row><row><cell>Other</cell><cell>2 (1.3)</cell><cell>1 (0.2)</cell><cell>-</cell></row><row><cell>Received HMG-CoA reductase inhibitor (statin)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>with daptomycin, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>19 (12.8)</cell><cell>59 (14.3)</cell><cell>(6.4)</cell></row><row><cell>No</cell><cell>129 (86.6)</cell><cell>354 (85.5)</cell><cell>(93.6)</cell></row><row><cell>Unknown</cell><cell>1 (0.7)</cell><cell>1 (0.2)</cell><cell>-</cell></row><row><cell>Severe renal impairment (CrCl \30 mL/min)</cell><cell>18 (12.1)</cell><cell>76 (18.4)</cell><cell>(17.0)</cell></row><row><cell>at initiation of daptomycin therapy, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patients on dialysis at daptomycin initiation, n (%)</cell><cell>13 (8.7)</cell><cell>51 (12.3)</cell><cell>(12.8)</cell></row><row><cell>Any significant underlying diseases ([10% of patients in</cell><cell>133 (89.3)</cell><cell>378 (91.3)</cell><cell>(91.5)</cell></row><row><cell>every group), n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cardiovascular disease</cell><cell>93 (62.4)</cell><cell>322 (77.8)</cell><cell>(72.3)</cell></row><row><cell>Gastrointestinal disease</cell><cell>24 (16.1)</cell><cell>55 (13.3)</cell><cell>(14.9)</cell></row><row><cell>Pulmonary disease</cell><cell>21 (14.1)</cell><cell>51 (12.3)</cell><cell>(19.1)</cell></row><row><cell>Renal disease</cell><cell>25 (16.8)</cell><cell>83 (20.0)</cell><cell>(25.5)</cell></row><row><cell cols="4">BRLIE both right-and left-sided infective endocarditis, CrCl creatinine clearance, HMG-CoA 3-hydroxy-3-methylglutaryl-</cell></row><row><cell cols="4">coenzyme A, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis, SD standard deviation a Asian, Black and missing</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3</head><label>3</label><figDesc><div><p><s>Primary pathogens in patients with positive cultures</s></p></div></figDesc><table><row><cell>Primary pathogens</cell><cell>RIE</cell><cell>LIE</cell><cell>BRLIE</cell></row><row><cell></cell><cell>N 5 110, n (%)</cell><cell>N 5 274, n (%)</cell><cell>N 29, n (%)</cell></row><row><cell>Staphylococcus aureus</cell><cell>53 (48.2)</cell><cell>101 (36.9)</cell><cell>(37.9)</cell></row><row><cell>Methicillin susceptible</cell><cell>39 (35.5)</cell><cell>50 (18.2)</cell><cell>(24.1)</cell></row><row><cell>Methicillin resistant</cell><cell>11 (10.0)</cell><cell>39 (14.2)</cell><cell>(10.3)</cell></row><row><cell>Methicillin susceptibility unknown</cell><cell>3 (2.7)</cell><cell>12 (4.4)</cell><cell>(3.4)</cell></row><row><cell>Coagulase-negative staphylococci</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Staphylococcus epidermidis</cell><cell>30 (27.3)</cell><cell>49 (17.9)</cell><cell>(6.9)</cell></row><row><cell>Methicillin susceptible</cell><cell>5 (4.5)</cell><cell>5 (1.8)</cell><cell>-</cell></row><row><cell>Methicillin resistant</cell><cell>22 (20.0)</cell><cell>37 (13.5)</cell><cell>(3.4)</cell></row><row><cell>Methicillin susceptibility unknown</cell><cell>3 (2.7)</cell><cell>7 (2.6)</cell><cell>(3.4)</cell></row><row><cell>Other</cell><cell>13 (11.8)</cell><cell>32 (11.7)</cell><cell>(20.7)</cell></row><row><cell>Methicillin susceptible</cell><cell>3 (2.7)</cell><cell>5 (1.8)</cell><cell>(3.4)</cell></row><row><cell>Methicillin resistant</cell><cell>10 (9.1)</cell><cell>25 (9.1)</cell><cell>(6.9)</cell></row><row><cell>Methicillin susceptibility unknown</cell><cell>-</cell><cell>2 (0.7)</cell><cell>(10.3)</cell></row><row><cell>Staphylococcus species-coagulase not specified</cell><cell>1 (0.9)</cell><cell>2 (0.7)</cell><cell>-</cell></row><row><cell>Enterococcus faecium</cell><cell>-</cell><cell>7 (2.6)</cell><cell>(3.4)</cell></row><row><cell>Vancomycin susceptible</cell><cell>-</cell><cell>3 (1.1)</cell><cell>-</cell></row><row><cell>Vancomycin resistant</cell><cell>-</cell><cell>2 (0.7)</cell><cell>(3.4)</cell></row><row><cell>Vancomycin susceptibility unknown</cell><cell>-</cell><cell>2 (0.7)</cell><cell>-</cell></row><row><cell>Enterococcus faecalis</cell><cell>6 (5.5)</cell><cell>34 (12.4)</cell><cell>(10.3)</cell></row><row><cell>Vancomycin susceptible</cell><cell>5 (4.5)</cell><cell>30 (10.9)</cell><cell>(6.9)</cell></row><row><cell>Vancomycin susceptibility unknown</cell><cell>1 (0.9)</cell><cell>4 (1.5)</cell><cell>(3.4)</cell></row><row><cell>Other Enterococcus species</cell><cell>-</cell><cell>7 (2.6)</cell><cell>-</cell></row><row><cell>Streptococcus agalactiae or group B streptococci</cell><cell>1 (0.9)</cell><cell>2 (0.7)</cell><cell>-</cell></row><row><cell>Streptococcus dysgalactiae</cell><cell>-</cell><cell>1 (0.4)</cell><cell>-</cell></row><row><cell>Streptococcus dysgalactiae equisimilis</cell><cell>-</cell><cell>1 (0.4)</cell><cell>-</cell></row><row><cell>Streptococcus pneumonia</cell><cell>-</cell><cell>1 (0.4)</cell><cell>-</cell></row><row><cell>Streptococcus pyogenes or group A streptococci</cell><cell>-</cell><cell>2 (0.7)</cell><cell>-</cell></row><row><cell>Streptococcus species</cell><cell>3 (2.7)</cell><cell>9 (3.3)</cell><cell>(3.4)</cell></row><row><cell>Viridians streptococci group</cell><cell>3 (2.7)</cell><cell>18 (6.6)</cell><cell>(6.9)</cell></row><row><cell>Gram-negative bacilli</cell><cell>-</cell><cell>2 (0.7)</cell><cell>(3.4)</cell></row><row><cell>Gram-positive cocci</cell><cell>-</cell><cell>2 (0.7)</cell><cell>(3.4)</cell></row><row><cell>Other a</cell><cell>-</cell><cell>4 (1.5)</cell><cell>(3.4)</cell></row><row><cell cols="4">BRLIE both right-and left-sided infective endocarditis, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis a Includes Corynebacterium species</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4</head><label>4</label><figDesc><div><p><s>Clinical outcomes in patients with infective endocarditis.</s><s>BRLIE both right-and left-sided infective endocarditis, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis Clinical success by type of endocarditis and dose groups (efficacy population)</s></p></div></figDesc><table><row><cell>). Patients</cell></row><row><cell>with RIE, LIE and BRLIE who had received a</cell></row><row><cell>daptomycin dose of 6 mg/kg/day had a median</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 5 .</head><label>5</label><figDesc></figDesc><table><row><cell>patients with RIE, LIE and BRLIE discontinued</cell></row><row><cell>daptomycin therapy due to AEs, respectively.</cell></row><row><cell>The numbers of reported AEs which were</cell></row><row><cell>related to daptomycin were low: 2 (1.3%) in</cell></row><row><cell>patients with RIE, 18 (4.3%) in patients with</cell></row><row><cell>LIE, and 1 (2.1%) patients with BRLIE. Among</cell></row><row><cell>AEs reported as related to daptomycin, creatine</cell></row><row><cell>phosphokinase (CPK) elevation was observed in</cell></row><row><cell>2 (1.3%), 8 (1.9%) and 1 (2.1%) patients, with</cell></row><row><cell>RIE, LIE and BRLIE, respectively. Two patients</cell></row><row><cell>(LIE) developed eosinophilic pneumonia. Death</cell></row><row><cell>was reported in 5 (3.4%), 53 (12.8%) and 7</cell></row><row><cell>(14.9%) patients with RIE, LIE and BRLIE,</cell></row><row><cell>respectively; none of the SAEs associated with</cell></row><row><cell>deaths were considered to be related to</cell></row><row><cell>daptomycin.</cell></row></table><note><p><s>Overall, 5 (3.4%), 30 (7.2%) and 2 (4.3%)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 5</head><label>5</label><figDesc><div><p><s>Summary of adverse events (safety population)</s></p></div></figDesc><table><row><cell>Safety parameters</cell><cell>RIE</cell><cell>LIE</cell><cell>BRLIE</cell></row><row><cell></cell><cell>N 5 149, n (%)</cell><cell>N 5 414, n (%)</cell><cell>N 5 47, n (%)</cell></row><row><cell>AEs</cell><cell>16 (10.7)</cell><cell>98 (23.7)</cell><cell>10 (21.3)</cell></row><row><cell>SAEs</cell><cell>9 (6.0)</cell><cell>70 (16.9)</cell><cell>10 (21.3)</cell></row><row><cell>Discontinuations due to AEs</cell><cell>5 (3.4))</cell><cell>30 (7.2)</cell><cell>2 (4.3)</cell></row><row><cell>AEs possibly related to daptomycin, n (%)</cell><cell>2 (1.3)</cell><cell>18 (4.3)</cell><cell>1 (2.1)</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>This study and article processing charges were sponsored by Novartis Pharma AG.</s><s>All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Compliance with ethics guidelines.</s></p><p><s>The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.</s><s>The protocol was approved by the health authority and the Institutional Review Board (IRB) or Ethics Committee (EC) in each country and written informed consent was obtained according to the requirements of the IRB or EC and/or the local data privacy regulations.</s></p><p><s>Open Access.</s><s>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Highdose daptomycin therapy for staphylococcal endocarditis and when to apply it</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Claeys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Barber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Rybak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Infect Dis Rep</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">429</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Infective endocarditis in the</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Bor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Woolhandler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brusch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">U</forename><surname>Himmelstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">e60033</biblScope>
			<date type="published" when="1998">1998-2009. 2013</date>
		</imprint>
	</monogr>
	<note>: a nationwide study</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Changing profile of infective endocarditis: results of a 1-year survey in France</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alla</forename><forename type="middle">F</forename><surname>Selton-Suty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="75" to="81" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Changing patient characteristics and the effect on mortality in endocarditis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Cabell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Jollis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Peterson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="90" to="94" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Murdoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Corey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hoen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="463" to="473" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey</title>
		<author>
			<persName><forename type="first">C</forename><surname>Selton-Suty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Celard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Moing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1230" to="1239" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Daptomycin use in pediatric patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Durand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brueckner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sampadian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Willett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Belliveau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Health Syst Pharm</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1177" to="1182" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Daptomycin therapy for invasive Gram-positive bacterial infections in children</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Ardura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mejias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Infect Dis J</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1128" to="1132" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Community-associated methicillin-resistant Staphylococcus aureus bacteremia and endocarditis among HIV patients: a cohort study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Furuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Schweizer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">298</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Laupland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Lyytikainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sogaard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="465" to="471" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Daptomycin for the treatment of infective endocarditis: results from a European registry</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Dohmen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guleri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Capone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="936" to="942" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Methicillin-resistant versus methicillin-sensitive Staphylococcus aureus infective endocarditis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Peetermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vanderschueren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="445" to="450" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Daptomycin: evaluation of a high-dose treatment strategy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rapp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="192" to="196" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillinresistant Staphylococcus aureus bacteremia before switching therapy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kullar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mckinnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sakoulas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1455" to="1461" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Infective endocarditis</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Que</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moreillon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cardiol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="322" to="336" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Update on daptomycin: the first approved lipopeptide antibiotic</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Kuti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Nicolau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Pharmacother</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1381" to="1397" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">G</forename><surname>Fowler</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Corey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="653" to="665" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Daptomycin in the treatment of patients with infective endocarditis: experience from a registry</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Lamp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="S28" to="33" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>Suppl 1</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Use of daptomycin in complicated cases of infective endocarditis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Saluja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Steeds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="807" to="812" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Treatment of Gram-positive left-sided infective endocarditis with daptomycin</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yilmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kalkan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ertunc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Koksal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Chemother</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="698" to="702" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Carugati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Bayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Miro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="6213" to="6222" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gonzalez-Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Beiras-Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lehmkuhl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="372" to="378" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Seaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Gonzalez-Ramallo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Prisco</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="468" to="472" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Seaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Malizos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Viale</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1642" to="1649" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">New criteria for diagnosis of infective endocarditis-utilization of specific echocardiographic findings</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Durack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Lukes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Bright</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="200" to="209" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Habib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tornos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="2369" to="2413" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Martone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Lindfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Pract</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1183" to="1187" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary</title>
		<author>
			<persName><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Cosgrove</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="285" to="292" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Laplante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Woodmansee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3880" to="3886" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Federspiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Miro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">200</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1355" to="1366" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cervera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Castaneda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pericas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="365" to="370" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycinresistant derivatives</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Plata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="6192" to="6200" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillinresistant Staphylococcus aureus endocarditis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Miro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Entenza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Del Rio</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="4511" to="4515" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
